



JUBILANT ORGANOSYS LIMITED

Registered Office: Bhartiagram, Gajraula - 244 223
District Jyotiba Phoolay Nagar,
Uttar Pradesh, India

NOTICE

NOTICE is hereby given that the Thirty Second Annual General Meeting of members of Jubilant Organosys Limited will be held as under: -

DAY : **TUESDAY**
DATE : **SEPTEMBER 28, 2010**
TIME : **11:30 A.M.**
VENUE : **REGISTERED OFFICE:
BHARTIAGRAM, GAJRAULA - 244 223
DISTRICT JYOTIBA PHOOLAY NAGAR,
UTTAR PRADESH, INDIA**

to transact the following business:-

ORDINARY BUSINESS

1. To consider and adopt the Balance Sheet of the Company as at March 31, 2010, the Profit and Loss Account for the year ended on that date and the Reports of the Auditors and Directors thereon.
2. To declare dividend.
3. To appoint a Director in place of Mr. Shyam S. Bhartia, who retires by rotation and, being eligible, offers himself for re-appointment.
4. To appoint a Director in place of Mr. Arabinda Ray, who retires by rotation and, being eligible, offers himself for re-appointment.
5. To appoint a Director in place of Mr. Surendra Singh, who retires by rotation and, being eligible, offers himself for re-appointment.
6. To consider and, if thought fit, to pass, with or without modification(s), the following resolution as an **Ordinary Resolution:**

“RESOLVED THAT M/s. K. N. Gutgutia & Co., Chartered Accountants (Firm Registration Number 304153E with the Institute of Chartered Accountant of India), the Statutory Auditors of the Company, who retire but, being eligible, offer themselves for re-appointment, be and are hereby re-appointed as Auditors of the Company to hold office from the conclusion of 32nd Annual General Meeting until the conclusion of next Annual General Meeting on such remuneration as agreed upon by the Board of Directors and the Auditors, in addition to the reimbursement of service tax and actual out-of-pocket expenses.”

SPECIAL BUSINESS

7. To consider and, if thought fit, to pass, with or without modification(s), the following resolution as an **Ordinary Resolution:**

“RESOLVED THAT Dr. Inder Mohan Verma be and is hereby appointed as a Director of the Company.”

8. To consider and, if thought fit, to pass, with or without modification(s), the following resolution as an **Ordinary Resolution:**

“RESOLVED THAT Mr. Shardul S. Shroff be and is hereby appointed as a Director of the Company.”

9. To consider and, if thought fit, to pass, with or without modification(s), the following resolution as a **Special Resolution:**

“RESOLVED THAT pursuant to Sections 309, 310 and other applicable provisions of the Companies Act, 1956, if any, and subject to the approval of Central Government, if required, approval be and is hereby accorded to the payment of commission to directors other than the Managing/Executive Directors (hereinafter called the “Non-Executive Directors”) not exceeding in the aggregate, one per cent per annum of the net profits of the Company, to be paid to and distributed amongst the Non-Executive Directors in such amounts or proportions and in such manner as the Board of Directors may determine, subject to a maximum of ₹ 5,00,000 per annum to any such Non-Executive Director, calculated in accordance with the provisions of Sections 198, 349 and 350 of the Act, and such payment shall be made in respect of the profits of the Company for each of the five years commencing from April 1, 2010.

RESOLVED FURTHER THAT for the purpose of giving effect to the above, the Board of Directors be and is hereby authorised to do all such acts, deeds, matters and things as may be necessary or expedient in this regard”

10. To consider and, if thought fit, to pass, with or without modification(s), the following resolution as a **Special Resolution:**

“RESOLVED THAT pursuant to provisions of Section 31 and other applicable provisions, if any, of the Companies Act, 1956, the Articles of Association of the Company be altered by substituting the existing Articles 186 to Article 190 under the Heading “SPECIAL PROVISIONS” with new Articles 186 to Article 190 as follows:

SPECIAL PROVISIONS

OVERRIDING EFFECT

186. The provisions of this part shall have effect notwithstanding anything contained in this Articles of

Association and in the event of any conflict between the provisions of this part and any other provisions, the provisions of this part shall prevail.

DEFINITIONS

187. The following terms shall have the meaning attributed to them below:

“**Affiliate**” means, in relation to any person, any entity controlled, directly or indirectly, by that person, any entity that controls, directly or indirectly, that person, or any entity under common control with that person or, in the case of a natural person, any Relative (as such term is defined in the Act) of such person.

For the purpose of this definition:

- (i) “**Control**” means the power to direct the management and policies of an entity whether through the ownership of voting capital, by contract or otherwise, and
- (ii) a holding or subsidiary company of any entity shall be deemed to be an Affiliate of that entity;

“**Connected Persons/Concern**” of the Company includes:

- (i) any company under the same management (as defined by Section 370 (1-B) of the Act) as the Company;
- (ii) the Promoters or any Affiliate of the Promoters;
- (iii) any person having control or significant influence over the Company as defined in Accounting Standard 18 issued by the Institute of Chartered Accountants of India;
- (iv) any related party to the Company as contemplated in sections 295 - 301 of the Companies Act, 1956.

Provided that, for purposes of these Articles the term “**Connected Persons/Concern**” shall not include any Subsidiary of the Company.

NOTE: For the purpose of the above, the Investor Director and the independent directors (as defined in the Listing Agreement applicable to the Company) shall not be deemed to be directors of the Company.

“**Equity Shares**” means equity shares of the Company having a face value of ₹ 1 per equity share;

“**GA**” means GA European Investments Limited, a company incorporated under the laws of Cyprus, having its registered office at Papyros Building, 6 Themistocles Dervis Street, Office No. 4, 3rd Floor, Nicosia CY-1066, Cyprus, and shall, unless it be repugnant to the context or meaning thereof, be deemed to mean and include its successors and assigns;

“**Investor**” means GA;

“**Investor’s Consent**” means the prior written consent of the Investor;

“**Investor Group**” means the Investor and any Affiliate(s) of such Investor;

“**Investor’s Shares**” means the Equity Shares of the Company held by the Investor and/or any member of the Investor Group from time to time, including the Equity Shares subscribed to by the Investor under the terms of its Agreement and any other Equity Shares purchased by the Investor or any member of the Investor Group at any time, so long as such Equity Shares are held by the Investor or a member of the Investor Group.

For the avoidance of doubt, for purposes of these Articles and the rights granted to the Investor hereunder, it is intended to restrict the term “**Investor’s Shares**” to the number of Equity Shares specified in this definition, notwithstanding that the Investor may actually hold Equity Shares in excess of the number prescribed herein;

“**Law**” includes all statutes, enactments, acts of legislature or parliament, laws, ordinances, rules, bye-laws, regulations, notifications, guidelines, policies, directions, directives and orders of any Government, statutory authority, tribunal, board, court or recognised stock exchange and, if applicable, international treaties and regulations;

“**Minimum Holding Condition**” means the conditions that (i) the Investor Group should collectively continue to hold at least 72,00,000 Equity Shares (adjusted for any consolidation or reduction of capital) and (ii) the Equity Shares collectively held by the Investor Group should represent at least 5% of the then voting Equity Share capital of the Company.

“**Promoters**” means Jubilant Enpro Pvt. Limited, Vam Holdings Limited, Jubilant Capital Pvt. Limited, Jubilant Securities Pvt. Limited, Jaytee Pvt. Limited, Nikita Resources Pvt. Limited, Torino Overseas Limited, Rance Investment Holdings Limited, Cumin Investments Limited, Mr Shyam S. Bhartia, Mr. Hari S. Bhartia, Mr Priyavrat Bhartia, Mr Shamit Bhartia and Mrs Kavita Bhartia.

“**Reserved Matters**” shall mean:

- (i) Amend the Memorandum and Articles of Association of the Company in any manner that would adversely affect any of the rights, preferences, privileges or restrictions of the Investor.
- (ii) Enter into any major transactions of a cumulative value of ₹ 5,00,00,000/- in any Financial Year with any Connected Persons/Concern or any person other than subsidiaries of the Company, other than customary compensation arrangements for key management personnel (as defined in the Annual Report of the Company) and directors.
- (iii) Exceed a debt:equity ratio of 2:1 (provided that the USD 200 Million FCCBs issued by the Company shall be deemed to be equity for this purpose).

188. INVESTOR DIRECTOR

- (a) The Board shall at all times be constituted in accordance with all corporate governance norms, including the provisions of the listing agreements between the Company and the exchanges on which the Equity Shares of the Company are listed.
- (b) So long as the Minimum Holding Condition is satisfied by GA, it shall be entitled to appoint and maintain in office one director (and to remove from office any director so appointed and to appoint another in the place of the director so removed) ("GA Director").

GA Director is hereinafter called "Investor Director"

- (c) Any appointment or removal of Investor Director under this Article shall, subject to Law and unless the contrary intention appears, take effect from the date it is notified to the Company in writing. If the Law does not permit the person nominated by Investor to be appointed as a director of the Company merely by such nomination, the Company shall ensure that the Board forthwith (and in any event within 20 days of such nomination or at the next Board meeting, whichever is earlier) appoints such person as a director of the Company and further that, unless the Investor change or withdraw such nomination, such person is also elected as a director of the Company at the next general meeting of the shareholders of the Company.

Provided that no person shall be eligible for appointment as an Investor Director or an Investor Director if already appointed shall cease to continue as a director on the Board if:

- (i) Such person is appointed on the board of another company which is notified as a defaulting company by the Reserve Bank of India;
 - (ii) Such person is appointed on the board of any of the existing Lenders of the Company, being the persons agreed between the Company and the Investor; and
 - (iii) The Investor Director is conflicted in the manner agreed between the Company and the Investor.
- (d) In the event that an Investor Director is disqualified on account of (i), (ii) or (iii) above, subject to compliance with the Act, the Board shall have the right to cause the removal of such Investor Director (without any reference of the matter to the Investor) or at the request of the Board, the Investor shall remove or cause the resignation of such Investor Director from the Board and the Investor who earlier nominated him, may nominate another person as the Investor Director.
 - (e) Without prejudice to the above, the Company agrees to exercise all powers and rights available

to them so as to fix the number of directors in accordance with this Article 188 and to ensure that the person nominated by the Investor is expeditiously appointed or removed (as the Investor may specify) as a director of the Company and the appointments and removals referred to in this Article 188 result in the person nominated / appointed or removed becoming or ceasing to be a director on the Board.

- (f) The Investor Director shall be entitled to be member of the audit committee (by whatsoever name so called) of the Board ("Audit Committee").
- (g) Subject to the relevant provisions of the Act, the Company shall pay the Investor Director all reasonable out of pocket expenses (including international air fares) incurred in order to attend any board or Audit Committee meetings of the Company or otherwise perform his duties and functions as a director of the Company and as member of the Audit Committee.
- (h) The Company shall indemnify the Investor Director against:-
 - (i) any act, omission or conduct of or by the Company, its employees or agents, or the Promoters as a result of which, in whole or in part, an Investor Director is made a party to, or otherwise incurs any loss pursuant to, any action, suit, claim or proceeding arising out of or relating to any such conduct; or
 - (ii) any action or failure to act undertaken by an Investor Director at the request of or with the consent of the Company, the managing directors, the executive directors or the company secretary of the Company; or
 - (iii) contravention of any Law including, without limiting the generality of the foregoing, the Foreign Exchange (Management) Act 1999, Laws relating to provident fund, gratuity, labour, environment and pollution; and any action or proceedings taken against an Investor Director in connection with any such contravention or alleged contravention. Provided that the Company shall not be under any obligation to indemnify an Investor Director under this Article 188 if the contravention is attributable to gross negligence or wilful misconduct of such Investor Director.

189. RESERVED MATTERS

As long as the Minimum Holding Condition is satisfied by the Investor, no action relating to any of the Reserved Matters shall be taken (whether by the Board, any committee, the shareholders of the Company or any of the employees, officers or managers of the Company) unless the Investor's Consent is obtained for such action, and all decisions relating to any Reserved Matter shall be subject to the Investor's Consent.

190. RESTRICTION ON SHARE TRANSFER

(a) In the event that the Promoters (or any of them), sell any of their Equity Shares, consequent to which the Promoters' shareholding falls below 33% of the Equity Share capital of the Company (including by way of enforcement of security or otherwise), (including any sale of Equity Shares where the Promoters' shareholding is already below 33% of the Equity Share capital):

- (i) the Promoters shall first give a written notice (hereinafter referred to as "Offer Notice") to the Investor. The Offer Notice shall state (i) the number of Equity Shares proposed to be transferred (hereinafter referred to as the "Sale Shares") and the number and class of Equity Shares the Promoters own at that time, (ii) the name and address of the proposed transferee, (iii) the proposed price, including the proposed amount and form of consideration and terms and conditions offered by such proposed transferee, (iv) the date of consummation of the proposed transfer, (v) a representation that the proposed transferee has been informed of the "tag-along" rights provided for in these Articles and has agreed to purchase all the Equity Shares required to be purchased in accordance with the terms of this Article, and (vi) a representation that no consideration, tangible or intangible, is being provided to the Promoter that will not be reflected in the price paid to the Investor on exercise of tag-along rights hereunder. In the event that the proposed consideration for the transfer includes consideration other than cash, the Transfer Notice shall include a calculation of the fair market value of such consideration and an explanation of the basis for such calculation. The total value of the consideration for the proposed transfer is referred to herein as the "Offer Price". Such notice shall be accompanied by a warranty from the Promoters that the contents of the Offer Notice are true and complete.
- (ii) The Investor shall be entitled to respond to the Offer Notice by serving a written notice ("the Response Notice") on the Promoter prior to the expiry of 30 Business Days from the date of receipt of the Offer Notice ("Offer Period") requiring the Promoter to ensure that the proposed transferee of the Sale Shares also purchases such number of the Equity Shares as mentioned in the Response Notice at the same price and on the same terms as are mentioned in the Offer Notice. It is clarified that the Investor may offer all or any of the Equity Shares held by him in the Offer Notice.
- (iii) The Promoter shall not be entitled to sell or transfer any of the Sale Shares to

any proposed purchaser / transferee unless the proposed purchaser / transferee simultaneously purchases and pays for all the Equity Shares mentioned in the Response Notice for the same consideration and upon the same terms and conditions as applicable to the Sale Shares, provided that the Investor may choose to receive the cash equivalent of any such consideration which is in a form other than cash.

- (iv) In the event that the Investor does not deliver a Response Notice to the Promoter prior to the expiry of the Offer Period, then, upon the expiry of the Offer Period, the Selling Shareholder shall be entitled to sell and transfer the Sale Shares to the proposed transferee mentioned in the Offer Notice on the same terms and conditions and for the same consideration as is specified in the Offer Notice. Any transferee purchasing the Offered Shares shall deliver to the Promoter on or before the date of consummation of the proposed transfer specified in the Offer Notice payment in full of the Offer Price in accordance with the terms set forth in the Offer Notice and any requisite transfer taxes. If completion of the sale and transfer to the proposed transferee does not take place within the period of 90 days following the expiry of the Offer Period (unless an additional period of time is required under applicable Law to complete such transfer), the Promoter's right to sell the Sale Shares to such third party shall lapse and the provisions of Article 190(b)(i) shall once again apply to the Sale Shares. Additionally, at least six months should pass between two successive Offer Notices for sale of the Sale Shares.
- (v) Where an Investor requires prior legal, governmental, regulatory or shareholder consent for the disposal of Equity Shares pursuant to these Articles then notwithstanding anything to the contrary, the Investor shall only be obliged to acquire or dispose of Equity Shares once such consent or approval is obtained, and the concerned parties shall use their reasonable endeavours to obtain any such required approvals. Any period within which a transfer of Equity Shares by or to the Investor has to be completed shall be extended by such further period as is necessary for the purpose of obtaining the above approvals. Provided that if any of the abovementioned approvals are finally withheld, then the Investor that did not receive such approval shall be deemed not to have offered to sell the concerned Equity Shares.

- (b) In the event that the Promoters transfer shares (including by way of enforcement of security or

otherwise) representing 10% or more of the then Equity Share capital of the Company ("Block Sale Percentage") in a single or a series of transactions in any financial year then:

- (i) The Promoters shall provide the Investor with an Offer Notice containing the items mentioned at Article 190(a)(i) above;
- (ii) The Investor shall be entitled to respond to the offer Notice by serving a written notice ("the Response Notice") on the Promoters prior to the expiry of 30 days from the date of the Offer Notice ("Offer Period") requiring the Promoters to ensure that the proposed transferee of the Sale Shares also purchases all or some of the Investor's Shares as mentioned in the Response Notice at the same price and on the same terms as are mentioned in the Offer Notice.
- (iii) The Promoters shall ensure that, along with the Sale Shares, the proposed transferee also acquires the Equity Shares specified in the Response Notice for the same consideration and upon the same terms and conditions as applicable to the Sale Shares, provided that the Investor may choose to receive the cash equivalent of any such consideration which is in a form other than cash. If the proposed transferee(s) is/are unwilling or unable to acquire all of the securities mentioned in the Response Notice upon such terms, then the Promoters may elect either to cancel such proposed transfer or to allocate the maximum number of Equity Shares of the Company which the proposed transferee is willing to purchase among the Sale Shares and the Equity Shares specified by the Investor in the Response Notice pro-rata in the ratio of the Equity Shareholding in the Company at such time of the selling Promoter and the Investor's Shares applicable to each Investor and to consummate such transfer on such terms. The Promoters shall not be entitled to sell or transfer any of the Sale Shares to any proposed purchaser/transferee unless the propose purchaser/transferee simultaneously purchases and pays for the required number of Equity Shares mentioned in the Response Notice in accordance with the provisions of this Article.
- (iv) In the event that the Investor does not deliver a Response Notice to the Promoter prior to the expiry of the Offer Period, then, upon the expiry of the Offer Period, the Selling Shareholder shall be entitled to sell and transfer the Sale Shares to the proposed transferee mentioned in the Offer Notice on the same terms and conditions and for the same consideration as is specified in the Offer Notice. Any transferee purchasing the Offered

Shares shall deliver to the Promoter on or before the date of consummation of the proposed Transfer specified in the Offer Notice payment in full of the Offer Price in accordance with the terms set forth in the Offer Notice and any requisite transfer taxes. If completion of the sale and transfer to the proposed transferee does not take place within the period of 90 days (unless an additional period of time is required under applicable Law to complete such transfer) following the expiry of the Offer Period, the Promoter's right to sell the Sale Shares to such third party shall lapse and the provisions of Article 190(b)(i) shall once again apply to the Sale Shares. Additionally, at least six months should pass between two successive Offer Notices for sale of the Sale Shares.

- (v) Where the Investor requires prior legal, governmental, regulatory or shareholder consent for the disposal of Equity Shares pursuant to these Articles then notwithstanding anything to the contrary the Investor shall only be obliged to acquire or dispose of Equity Shares once such consent or approval is obtained, and the concerned parties shall use their reasonable endeavours to obtain any such required approvals. Any period within which a transfer of Equity Shares by or to the Investor has to be completed shall be extended by such further period as is necessary for the purpose of obtaining the above approvals. Provided that if any of the abovementioned approvals are finally withheld, then the Investor that did not receive such approval shall be deemed not to have offered to sell the concerned Equity Shares.
- (c) The Promoters agree that the Transfer restrictions in these Articles shall not be capable of being avoided by the holding of Equity Shares indirectly through a company or other entity that can itself be sold in order to dispose of an interest in Equity Shares free of such restrictions.

RESOLVED FURTHER THAT for the purpose of giving effect to the above, the Board of Directors be and is hereby authorised to do all such acts, deeds, matters and things as may be necessary or expedient in this regard".

11. To consider and, if thought fit, to pass, with or without modification(s), the following resolution as a **Special Resolution**:

"RESOLVED THAT in accordance with Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999, and any other applicable laws for the time being in force, consent be and is hereby accorded to modify Jubilant Employees Stock Option Plan 2005 ("**Plan**") by inserting the following Clause 12B, after existing Clause 12A:

12B.Special provisions consequential to demerger of the Demerged Undertaking (as defined in the Scheme) with Jubilant Industries Limited

Pursuant to the Scheme of Amalgamation and Demerger between the Company, Speciality Molecules Limited, Pace Marketing Specialities Limited and Jubilant Industries Limited (“Scheme”), the Demerged Undertaking (as defined in the Scheme) of the Company shall *inter-alia* vest with Jubilant Industries Limited (“JIL”) from the Effective Date (as defined in the Scheme). Upon the Scheme coming into effect on the Effective Date and with effect from the Demerger Appointed Date (as defined in the Scheme), all persons that were employed in the Demerged Undertaking immediately before such date, shall become employees of JIL and the following special provisions will apply:

12B.1 For Participants continuing to be Employees.

- (a) In respect of Options granted and vested in a Participant on or before the Effective Date (as defined in the Scheme) but not exercised upto the Demerger Record Date, such Participant will be entitled to exercise these Options during the Exercise Period. Upon such exercise, the Participant will be entitled to acquire from the Company / Trust -
 - (i) Such number of Shares to which the Participant is entitled in accordance with the Plan, upon full payment of the Exercise Price and taxes, if any, required to be deducted by the Company in respect of exercise of the Options; and
 - (ii) One equity share of face value of ₹ 10/- of JIL (“JIL Shares”), without any payment, for every 20 Shares acquired pursuant to (i) above. It is hereby clarified that no JIL Shares shall be issued / transferred by the Company/ Trust under this sub-clause to any Participant, in respect of fractional entitlements, if any, of such Participant.
- (b) In respect of Options granted but not vested prior to the Effective Date, a Participant will be entitled to exercise these Options after vesting of such Options, during the Exercise Period. Upon such exercise, if such exercise is after the Demerger Record Date, such Participant will be entitled to acquire from the Company / Trust -
 - (i) Such number of Shares to which he is entitled in accordance with the Plan, upon full payment of the Exercise Price and taxes, if any, required to be deducted by the Company in respect of exercise of the Options; and
 - (ii) One JIL Share, without any payment, for every 20 Shares acquired pursuant to (i) above. It is hereby clarified that no JIL Shares shall be issued / transferred by the Company/ Trust under this sub-clause to any Participant, in respect of fractional entitlements, if any, of such Participant.

- (c) In respect of Options to be granted after the Effective Date, a Participant shall not be entitled to any JIL Share.
- (d) The Lock-in provisions, in accordance with the Plan, wherever applicable to the Shares of the Company, will also apply to the JIL Shares acquired by such Participant.

12B.2 For employees of the Company or the Group, transferred to JIL upon the Scheme coming into effect from the Effective Date and with effect from the Demerger Appointed Date.

- (a) In respect of Options vested in a Participant on or before the Effective Date but not exercised upto the Demerger Record Date, such Participant will be entitled to exercise the Options during the Exercise Period. Upon such exercise, if such exercise is after the Demerger Record Date, the Participant will be entitled to acquire from the Company / Trust -
 - (i) Such number of Shares to which he is entitled in accordance with the Plan, upon full payment of the Exercise Price and taxes, if any, required to be deducted by the Company in respect of exercise of the Options; and
 - (ii) One JIL Share, without any payment, for every 20 Shares acquired pursuant to (i) above. It is hereby clarified that no JIL Shares shall be issued / transferred by the Company/ Trust under this sub-clause to any Participant, in respect of fractional entitlements, if any, of such Participant.

The Lock-in provisions, in accordance with the Plan, wherever applicable to the Shares of the Company, will also apply to the JIL Shares acquired by such Participant.
- (b) In respect of Options granted but not vested upto the Effective Date, the Unvested Options granted to such Participant who is scheduled to be transferred to JIL pursuant to the Scheme coming into effect, shall automatically vest in him on the Effective Date provided that such Options were granted at least one year prior to that Date. Such Participant will be entitled to exercise the Options during the Exercise Period. Upon such exercise, if such exercise is after the Demerger Record Date, the Participant will be entitled to acquire from the Company / Trust -
 - (i) Such number of Shares to which he is entitled in accordance with the Plan, upon full payment of the Exercise Price and taxes, if any, required to be deducted by the Company in respect of exercise of the Options; and
 - (ii) One JIL Share, without any payment, for every 20 Shares acquired pursuant to (i) above. It is hereby clarified that no JIL Shares shall be issued / transferred by the Company/

Trust under this sub-clause to any Participant, in respect of fractional entitlements, if any, of such Participant.

The Shares of the Company / JIL Shares to be allotted / transferred on exercise of these Options shall be subject to a Lock- in period in accordance with the following schedule:

S. No.	% of total Options granted	Lock in period
i)	First 10%	No lock in period
ii)	Next 15%	From the date of allotment/transfer of Shares upto the second anniversary of the Grant Date
iii)	Next 20%	From the date of allotment/transfer of Shares upto the third anniversary of the Grant Date
iv)	Next 25%	From the date of allotment/transfer of Shares upto the fourth anniversary of the Grant Date
v)	Next 30%	From the date of allotment/transfer of Shares upto the fifth anniversary of the Grant Date

(c) In respect of Options granted less than one year prior to the Effective Date of the Scheme and not vested upto the Effective Date, such Options will automatically lapse on that Date.

(d) In respect of such employees who have been transferred to JIL, any reference to the term 'Group' will include a reference to 'JIL', for the purposes of the provisions of Clause 12 (with respect to Options granted upto August 28, 2009) and Clause 12A (with respect to Options granted after August 28, 2009).

12B.3 The provisions of Clause 12B shall come into effect only upon the Scheme coming into effect on the Effective Date. In the event of any conflict between the provisions of Clause 12.B and any other clauses of the Plan, in relation to employees of the Company or the Group, transferred to JIL upon the Scheme coming into effect from the Effective Date, the provisions of Clause 12.B shall apply.

RESOLVED FURTHER THAT for the purpose of giving effect to the above, the Board of Directors (including Compensation Committee) be and is hereby authorised to do all such acts, deeds, matters and things as may be necessary or expedient in this regard".

By Order of the Board
for Jubilant Organosys Limited

Lalit Jain
Company Secretary

July 27, 2010

Notes:

1. Explanatory Statement, pursuant to Section 173(2) of the Companies Act, 1956, in respect of Resolutions set out under item nos. 7 to 11 above, is annexed.
2. Information regarding the Directors proposed to be appointed/re-appointed pursuant to Clause 49 (IV) (G) of the Listing Agreement with stock exchanges is annexed.
3. A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND ON POLL, TO VOTE INSTEAD OF HIMSELF/ HERSELF. A PROXY NEED NOT BE A MEMBER.

PROXIES IN ORDER TO BE EFFECTIVE MUST BE RECEIVED AT THE REGISTERED OFFICE OF THE COMPANY NOT LESS THAN FORTY-EIGHT HOURS BEFORE THE COMMENCEMENT OF THE MEETING. MEMBERS/PROXIES SHOULD FILL THE ATTENDANCE SLIP FOR ATTENDING THE MEETING.

4. Corporate members intending to send their authorised representatives to attend the Meeting are requested to send a certified copy of the Board Resolution authorising their representative to attend and vote on their behalf at the Meeting.
5. The Register of members of the Company shall remain closed from Tuesday, September 21, 2010 to Tuesday, September 28, 2010 (both days inclusive) for the purpose of determining eligibility for payment of dividend.
 - (i) The dividend, as recommended by the Board (₹ 2 per equity share of ₹ 1 each), if declared at the meeting, will be paid to those members or their mandates:

- a. whose names appear as Beneficial owners as at the end of business hours on Monday, September 20, 2010 in the lists of Beneficial Owners furnished by National Securities Depository Limited and Central Depository Services (India) Limited in respect of the shares held in electronic form; and
- b. whose names appear as Members in the Register of members of the Company after giving effect to valid share transfers in physical form lodged with the Company on or before Monday, September 20, 2010.

(ii) **Change of address or other particulars**

Members are requested to inform their change of address (with PIN Code), nominations, bank details, mandate instructions, Electronic Clearing Service (ECS) mandates etc. as also any changes in the above (*under the signature of the registered holder(s) of shares*) to:-

- The Registrar and Share Transfer Agent (RTA) of the Company in respect of shares held in physical form; and

- The Depository Participants in respect of shares held in electronic form.

(iii) **Payment of Dividend Electronically**

Dividend will be paid, preferably through ECS, wherever such facility is available, under intimation to the shareholders. In case dividend cannot be paid through ECS, it will be paid through dividend warrants.

In cases where the payments to the shareholders holding shares in dematerialized form are made by dividend warrants / payment instruments, particulars of bank account registered with their Depository Participants will be considered by the Company for printing the same on dividend warrants / payment instruments.

(iv) **Bank Mandate**

In order to provide protection against fraudulent encashment of dividend warrants, members who hold shares in physical form are requested to intimate the Company's RTA under the signature of the Sole / First joint holder, the following information to be incorporated on the dividend warrants:

- Name of Sole / First joint holder
- Folio Number.
- Particulars of Bank account, viz.:
 - Name of the Bank
 - Name of the Branch
 - Complete address of the Bank with PIN Code
 - Account type, whether savings or current account
 - Bank account number

6. Dividends pertaining to the financial years upto and including 1993-94, remaining unclaimed, have been transferred to the General Revenue Account of the Central Government. Shareholders having valid claims of unpaid dividend for any of those financial years, may approach the Registrar of Companies, U.P. and Uttarakhand, Kanpur.

Dividends pertaining to the financial years 1994-95 to 2001-02, remaining unpaid, have been transferred to the Investor Education and Protection Fund (the Fund) established under Section 205C of the Companies Act, 1956 (the Act). As per the said Section, no claims shall lie against the Fund or the Company for the amounts transferred as above.

Members may kindly note that unpaid/unclaimed dividend for the year 2002-03 is due for transfer to the Fund, in October, 2010. As informed earlier, no claims shall lie against the Fund or the Company for the amounts transferred to the Fund. Members are,

therefore, requested to lodge their claims with the RTA, well in advance to avoid any hardship.

- Members who hold shares in physical form in multiple folios with identical names or hold multiple joint accounts in the same order of names, are requested to send the share certificates to the Company's RTA for consolidation into a single folio.
- In terms of Section 109A of the Act, member(s) of the Company may nominate a person on whom the shares held by him / them shall vest in the event of his/ their unfortunate death. Member(s) desirous of availing this facility may submit nomination in Form 2B.
- Members are requested to inform us their e-mail address to enable us to send important communications such as un-audited financial results, press releases and other similar information soon after these are intimated to the stock exchanges.
- The Company has a dedicated e-mail address "investors@jubl.com" for shareholders to mail their queries or lodge complaints, if any. We will endeavor to reply to your queries at the earliest.
- The Company's website "www.jubl.com" has a dedicated section on Investors. It also answers your frequently asked questions.
- Certificate from Auditors regarding compliance of SEBI (ESOS & ESPS) Guidelines, 1999 shall be placed at the Annual General Meeting.
- SEBI has placed the Company's shares under compulsory demat i.e. transactions in the Company's shares are required to be done only in the demat form. Further, considering the advantages of scripless trading like exemption from stamp duty, elimination of bad deliveries, reduction in transaction costs, improved liquidity etc., members are requested to consider dematerialisation of their shareholding, if not already done, to avoid inconvenience in future.
- In view of sub-division of each equity share of ₹ 5/- into five equity shares of ₹ 1/- each w.e.f. March 24, 2006, members were requested to surrender their existing certificates, so as to get the new sub-divided share certificates. Many shareholders have still not surrendered the old ₹ 10/- share certificates of Ramganga Fertilizers Limited / Vam Organic Chemicals Limited / Jubilant Organosys Limited or ₹ 5/- share certificates of Jubilant Organosys Limited, for exchange with new share certificates of ₹ 1/- each as above. Members are, therefore, requested to send the old share certificates along with a covering letter to the RTA for release of new certificates of ₹ 1/- thereagainst.
- Queries on the Annual Report and operations of the Company, if any, may please be sent to the Company seven days prior to the date of the Meeting so that the answers may be provided at the Meeting.

16. All correspondence may be sent to the RTA at the following address:

Alankit Assignments Limited,
(Unit: Jubilant Organosys Limited)
Alankit House, 2E/21,
Jhandewalan Extension,
New Delhi - 110 055, India
Phone: +91 - 11 - 23541234 / 42541234
Fax: +91 - 11 - 42541967
Email : rta@alankit.com

17. Your feedback/comments on various services and suggestions for further improvement are welcome. You may fill up and submit the feedback form online on our website www.jubl.com.

EXPLANATORY STATEMENT PURSUANT TO SECTION 173 (2) OF THE COMPANIES ACT, 1956

ITEM NO. 7

Dr. Inder Mohan Verma, was co-opted by the Board as Additional Director with effect from January 21, 2010 pursuant to Section 260 of the Companies Act, 1956. Dr. Verma thus, holds office till the date of the ensuing Annual General Meeting.

Notice under Section 257 of the Companies Act, 1956 has been received from a member together with requisite deposit intending to propose Dr. Verma as a candidate for the office of Director.

Dr. Verma is concerned or interested in the Resolution. No other Director is concerned or interested in the Resolution.

The Board of Directors is of the view that appointment of Dr. Verma as a regular Director of the Company is in the best interests of the Company and its members and, therefore, commends the Resolution for approval.

ITEM NO. 8

Mr. Shardul S. Shroff, was co-opted by the Board as Additional Director with effect from March 15, 2010 pursuant to Section 260 of the Companies Act, 1956. Mr. Shroff thus, holds office till the date of the ensuing Annual General Meeting.

Notice under Section 257 of the Companies Act, 1956 has been received from a member together with requisite deposit intending to propose Mr. Shroff as a candidate for the office of Director.

Mr. Shroff is concerned or interested in the Resolution. No other Director is concerned or interested in the Resolution.

The Board of Directors is of the view that appointment of Mr. Shroff as a regular Director of the Company is in the best interests of the Company and its members and, therefore, commends the Resolution for approval.

ITEM NO. 9

The Company had been paying commission of ₹ 2,00,000 per annum each to the Non-Executive Directors in addition to sitting fees, as per approval of the Central Government which expired on March 31, 2010.

To partially compensate for the time and efforts required to be spent by the Non-Executive Directors to provide strategic inputs for the growth of business, approval of members is now sought for authorizing the Board of Directors to pay commission upto ₹ 5,00,000 per annum each to the Non-Executive Directors for another 5 years commencing from April 1, 2010. The aggregate of commission to all such directors in a year shall not exceed 1% of net profits of the Company for that year.

Under Section 309(4) of the Companies Act, 1956, such payment requires approval of members by way of a Special Resolution. Moreover, since the payment of commission in addition to sitting fees may be construed as an increase in remuneration, such payment may also require approval of Central Government under Section 310 of the Companies Act, 1956.

Mr. Abhay Havaldar, Mr. Arabinda Ray, Mr. H.K. Khan, Dr. Inder Mohan Verma, Dr. Naresh Trehan, Mr. Shardul S. Shroff and Mr. Surendra Singh, being Non-Executive Directors, may be deemed to be interested in the Resolution. No other director is concerned or interested in the Resolution.

The Board commends the Resolution for approval.

ITEM NO. 10

Presently, Articles 186 to 190 of the Articles of Association of the Company, under the heading "Special Provisions", give special rights to Citicorp International Finance Corporation and HPC (Mauritius) Limited and GA European Investment Limited ('Investors'), covering appointment of Investor Director, Alternate Director and Observer, restriction on share transfers, and obtaining of Investors' consents for certain transactions pursuant to the Investment Agreements entered into by the Company with the Investors.

The Agreements with HPC (Mauritius) Limited and Citicorp International Finance Corporation stand terminated as they have completely sold their shareholding in the Company. As such it is considered appropriate that the clauses related to them be deleted from the existing Articles. The alterations are fully set out in Resolution No. 10 of the Notice.

This resolution is being proposed as a Special Resolution in compliance with the requirements of Section 31 of the Companies Act, 1956, governing the alteration of Articles of Association.

In the opinion of the Board, the proposed amendments will be in the interest of the Company and its members.

None of the directors is concerned or interested in the Resolution.

Copies of the Memorandum & Articles of Association of the Company shall be available for inspection to the desirous members of the Company on any working day between 11:00 A.M. and 1:00 P.M. at the Registered Office of the Company.

The Board commends the Resolution for approval.

ITEM NO. 11

The Company's Board of Directors have approved the amalgamation of Speciality Molecules Ltd. ("SML") and Pace Marketing Specialities Limited ("PMSL") with the Company and demerger of the following Divisions of the Company : (i) Agri Products Division, consisting of (a) Single Super Phosphate and (b) Agro Chemical for Crop Products (ii) Performance Polymer Division, consisting of (a) Food Polymer (Solid PVA), (b) VP Latex and SBR Latex, (c) Consumer Products and (d) application Polymer Products and (iii) IMFL Division [(i), (ii) and (iii), collectively called the "Demerged Undertaking"] to Jubilant Industries Limited ("JIL"); as per terms and conditions mentioned in the Scheme of Amalgamation and Demerger ('the Scheme'). The Scheme will be effective upon getting requisite approvals and upon its sanction by Hon'ble High Court at Allahabad.

The Company presently has a subsisting employee stock option plan for its employees termed as the Jubilant Employees Stock Option Plan, 2005 ("Plan"). Pursuant to the Plan, Jubilant Employees Welfare Trust ("Trust") has been set up to acquire equity shares of the Company for transferring these to employees upon exercise of Options.

The Trust, to the extent it holds equity shares of the Company, shall be issued equity shares of the JIL pursuant to the Scheme in accordance with the share exchange ratio i.e. One equity share of ₹ 10 of JIL ("JIL Share") for every 20 equity shares of ₹ 1 of the Company held.

It is proposed that in respect of the Options granted prior to the Effective Date, but not exercised upto the Demerger Record Date, the Option holder who is continuing with the Company, would be entitled to not only the equity shares of the Company but also the equity shares of JIL in accordance with the share exchange ratio when such Option holder pays the exercise price in accordance with the Plan.

The Lock-in provisions, in accordance with the Plan, wherever applicable to the equity shares of the Company, will also apply to the JIL Shares acquired by a Participant.

With respect to employees transferred to JIL upon demerger:

- (i) In respect of Vested Options, the Option holder would be entitled to not only the equity shares of the Company but also the equity shares of JIL in accordance with the share exchange ratio. The Lock-in provisions wherever applicable will apply to the equity shares of the Company / JIL Shares.
- (ii) In respect of Options granted atleast one year before the Effective Date but not vested upto that Date, the vesting period of such Options shall be accelerated and such Options shall vest with the employee on the Effective Date. Upon exercise, if such exercise is after the Demerger Record Date, he would be entitled to not only the equity shares of the Company but also the equity shares of JIL in accordance with the share exchange ratio. Upon such accelerated vesting, the shares allotted / transferred to him will be subject to a lock-in period as detailed in the Resolution.
- (iii) Options that were granted less than one year before the Effective Date will automatically lapse.

Other terms of the Plan will remain unchanged.

Since the last grant of Options took place under the Plan in October 2009 and the Scheme is reasonably expected to come into effect only after October 2010, subject to receipt of appropriate consents and approvals, there would be no employee whose Options would lapse upon his transfer to JIL. Further, due to accelerated vesting, the employees who will be transferred to JIL, upon the Scheme becoming effective, would be beneficiaries of the proposed modifications. Hence, the proposed modifications to the Plan are not in any manner prejudicial/detrimental to the interests of the Participants/Grantees / Employees.

The following Directors of the Company who are holders of Options may be deemed to be interested in the Resolution:

Name of Director	Options held & Outstanding	Number of resultant Equity Shares
Mr. Arabinda Ray	700	3,500
Mr. Surendra Singh	2,500	12,500
Mr. H K Khan	5,000	25,000
Dr. Naresh Trehan	5,000	25,000
Mr. Shyamsundar Bang	10,305	51,525
Dr. Jag Mohan Khanna	11,647	58,235

Other Directors are not, in any way, concerned or interested in the Resolution.

A copy of Jubilant Employees Stock Option Plan 2005 shall be available for inspection to the desirous members of the Company on any working day between 11:00 A.M. and 1:00 P.M. at the Registered Office of the Company.

The Board commends the Resolution for approval.

INFORMATION REGARDING THE DIRECTORS PROPOSED TO BE APPOINTED/RE-APPOINTED PURSUANT TO CLAUSE 49 (IV) (G) OF THE LISTING AGREEMENT WITH STOCK EXCHANGES

1. Mr. SHYAM S. BHARTIA

Mr. Shyam S. Bhartia, 57 years, the Chairman and Managing Director, holds a bachelors's degree in Commerce from St. Xavier's College, Calcutta University. He is a qualified Cost and Works Accountant and a fellow member of the Institute of Cost and Works Accountants of India.

A leading industrialist of India, he has 32 years of experience and expertise in the Pharmaceuticals and Speciality Chemicals, Food, Oil and Gas (Exploration & Production), Aerospace and Information Technology sectors.

He has served on the Board of Governors of Indian Institute of Technology, Kanpur and Indian Institute of Management, Ahmedabad. He has also been the Chairman of the Chemicals Committee of FICCI and is currently a member of the Executive Committee of FICCI.

He has been associated with Jubilant Organosys Limited since its incorporation as a promoter Director. In 1981, he was elevated to the position of Managing Director and from 1999 he is Chairman and Managing Director of the Company.

He holds Directorships in following Companies:

Public Companies

- Jubilant Chemsys Limited
- Jubilant Infrastructure Limited
- Clinsys Clinical Research Limited
- Jubilant First Trust Healthcare Limited
- Jubilant Innovation (India) Limited
- Jubilant Foodworks Limited
- Vam Holdings Limited
- Geo-Enpro Petroleum Limited
- Lionel India Limited
- Zuari Industries Limited
- Chambal Fertilizers & Chemicals Limited
- ACME Tele Power Limited

Other Companies

- Jubilant Enpro Private Limited
- Enpro Oil Private Limited
- Jubilant Capital Private Limited
- Tower Promoters Private Limited
- Nikita Resources Private Limited
- Jaytee Private Limited
- B & M Hotbreads Private Limited
- B T Telecom (India) Private Limited
- Focus Brands Trading (India) Private Limited
- American Orient Capital Partners (India) Private Limited
- Jubilant Organosys (USA) Inc.
- PSI Supply NV
- Jubilant Pharmaceuticals NV
- Jubilant Pharma NV
- Jubilant Pharma Pte Ltd.
- Cadista Holdings Inc.
- Cadista Pharmaceuticals Inc.
- Clinsys Holdings Inc.
- Clinsys Clinical Research Inc.
- Hollister-Stier Laboratories LLC
- HSL Holdings Inc.
- Jubilant Discovery Services Inc.
- 6963196 Canada Inc.
- 6981364 Canada Inc.
- Jubilant Innovation (USA) Inc.
- DRAXIS Specialty Pharmaceuticals Inc.
- Draximage Limited, Cyprus

- Draximage (UK) Limited
- Draxis Pharma Inc.
- Deprenyl Inc., USA
- Jubilant Energy (Holding) B.V.
- Jubilant Energy Limited, Canada
- Jubilant Energy NV, Netherlands
- Safe Foods Corporation
- Putney Inc.
- CFCL Technologies Limited (Cayman Islands)
- CFCL Venture Limited (Cayman Islands)
- Jubilant Bhartia Foundation

Mr. Shyam S. Bhartia is Chairman of the Audit Committees of Clinsys Clinical Research Limited and ACME Tele Power Limited.

2. MR. ARABINDA RAY

Mr. Arabinda Ray, 80 years, is an independent Director of the Company. He has held senior management positions in engineering, steel and tea companies. He was a founder member and first honorary director of the Indian Institute of Packaging and was India's sole representative at the founding of the Asian Packaging Federation in Japan. Mr. Arabinda Ray has at various times been a non-executive director of SAIL, UBI and Garden Reach Shipbuilders and Engineers in addition to a number of other public and private sector companies. He has expertise in General Management. He has a long association with Jubilant, having been an Independent Director since 1981.

He has served on the board of governors of the National Institute of Bank Management and the executive council of the Institute of Financial Management and Research, Chennai. Mr. Arabinda Ray is the author of several books on the Indian management scenario, notably- The Indian Management in Search of a Style (EPW 1970), Fifty Years of Indian Management (OUP 1999) and Independence to Globalization: An Indian Manager's Journey (Anthem Press 2008).

He is presently a Director on the Board of SDV International Logistics Limited.

Mr. Ray is Chairman of the Audit Committee of Jubilant Organosys Limited.

Mr. Ray holds 3,500 Equity Shares in the Company. He also holds 700 Stock Options granted to him under Jubilant Employees Stock Option Plan 2005.

3. MR. SURENDRA SINGH

Mr. Surendra Singh, 72 years, is an independent Director of the Company. He has over 35 years of experience in the Indian Administrative Service, having held several key positions including Special Secretary to the Prime Minister of India and Cabinet Secretary to the Government of India. He has vast experience and expertise in the areas of general management and industrial relations. He has also served as an Executive

Director at the World Bank, where he chaired the Committee of the World Bank Directors on Development Effectiveness. He has served as a member of our Board since August 16, 2002.

His present Directorships in other companies are as follows:

NIIT Limited

NIIT Technologies Limited

NIIT Smart Serve Limited

CMC Limited

Mr. Singh is a member of Audit Committee & Investors' Grievance Committee of Jubilant Organosys Limited.

He is also a member of the Audit Committees of CMC Ltd., NIIT Ltd. and NIIT Technologies Ltd.

He is Chairman of Shareholders' Grievance Committee of NIIT Ltd. and a member of Shareholders' Grievance Committee of CMC Ltd.

He holds 12,500 Equity Shares in the Company. He also holds 2,500 Stock Options granted to him under Employees Stock Option Plan, 2005.

4. DR. INDER MOHAN VERMA

Dr. Inder Mohan Verma, 62 years, is an independent Director of the Company. He holds a masters' degree in biochemistry from Lucknow University and a doctorate from Weizmann Institute of Science, Rehovoth, Israel. Dr. Inder Mohan Verma completed his post-doctoral training under the Nobel laureate, Dr. David Baltimore, at the Massachusetts Institute of Technology, USA. Dr. Inder Mohan Verma joined the faculty of the Salk Institute, California in 1974, where he currently holds the Irwin and Joan Jacobs Chair in Exemplary Science and is also the director of the laboratory of genetics. Dr. Inder Mohan Verma and his colleagues have pioneered the development of a gene therapy vector based on a stripped-down version of HIV that can deliver genes to nondividing cells, which constitutes the majority of the cells in a human body. He has expertise in Genetics.

Dr. Inder Mohan Verma has been on the editorial boards of a number of international scientific journals and has served as founding editor-in-chief of Molecular Therapy, a journal that focuses on gene therapy. He has been conferred with many honours and awards including one of 25 Lifetime American Cancer Society Professorships (1990) and Outstanding Investigator Award from the National Institutes of Health, USA (1988). Dr. Inder Mohan Verma is also the recipient of the Cozzarelli Prize (2007), the Vilcek Prize (2008) and the Spector prize (2009). He was also conferred an honorary doctorate of science from the University of Hyderabad in 2009. Dr. Inder Mohan Verma is the member of National Academy of Sciences (USA), Institute of Medicine, American Philosophical Society and is foreign

associate of Indian Academy of Sciences. Dr. Inder Mohan Verma has published over 300 scientific articles.

Dr. Verma is presently a Director on the Board of Jubilant Biosys Limited.

He was appointed on Board of Jubilant Organosys Ltd. with effect from January 21, 2010.

He is not holding any Equity Shares in the Company.

5. MR. SHARDUL S. SHROFF

Mr. Shardul S. Shroff, 54 years, is an Independent Director on our Board. He holds a bachelor's degree in commerce from Sydenham College, Mumbai and an L.L.B. from Government Law College, Mumbai. Mr. Shroff is the Managing Partner of the law firm Amarchand & Mangaldas & Suresh A. Shroff & Co.

As a corporate attorney for 29 years, Mr. Shroff has extensive experience in areas of infrastructure, projects & project finance, privatization and disinvestment, mergers and acquisitions, joint ventures, banking and finance, capital markets and commercial contracts. Mr. Shroff is also a leading authority on legal matters related to corporate governance, media law, technology law and policy and regulatory practices. He has been a member of several Committees appointed by the Government of India, including the J.J. Irani Committee (2006) on corporate governance. Mr. Shroff also serves on a number of committees of the Confederation of Indian Industry (CII) and the Federation of Indian Chambers of Commerce and Industry (FICCI).

His Directorships in other companies are as follows:

Infrastructure Development Finance Company Limited

Jindal Power Limited

Ballarpur Industries Limited

Ashok Leyland Limited

Nokia HCL Mobile Internet Services Limited

Hindustan Media Ventures Limited

Mr. Shroff is member of the Audit Committee of Infrastructure Development Finance Company Limited.

He was appointed on Board of Jubilant Organosys Ltd. with effect from March 15, 2010.

He is not holding any Equity Shares in the Company.

By Order of the Board
For Jubilant Organosys Limited

Lalit Jain
Company Secretary

July 27, 2010